Artiva Biotherapeutics currently has no Cashu-related articles
Key Stats
Market Cap
119.62M
Dividend Yield
0.00%
P/E Ratio
-1.59
EPS
-38.81
Revenue
251.00K
Avg. Volume
24.40M
About
What does ARTV do?
Artiva Biotherapeutics, based in San Diego, focuses on NK cell-based therapies for autoimmune diseases and cancers, with its lead candidate AlloNK in Phase I/Ib trials. The company went public on July 19, 2024.
